Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOSCA: FOLFOX-4 Duration and Bevacizumab in Stage II/III Colon Cancer
NCT00646607Phase 3Completed
- Sponsor
- Fondazione Giscad per la Ricerca sui Tumori
- Start
- Jun 2007
- Primary completion
- Apr 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab in colon cancer, sponsored by Fondazione Giscad per la Ricerca sui Tumori. Started Jun 2007; status: completed.
02
Drugs
bevacizumab
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT00646607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00646607.